Cavitron W7 HP7 Pharma

Description

Cavitron cyclodextrins are manufactured and tested to meet low bioburden and endotoxin specifications.

Cavitron W7 HP7 Pharma HPBCD has slightly higher water solubility than Cavitron W7 HP5 Pharma HPBCD.

Benefits:

• Increase solubility and bioavailability in oral, parenteral, ophthalmic and liquid-dosage forms
• Provide low bioburden and endotoxin grades that meet defined limits for use in parenteral and ophthalmic dosage forms1
• Offer grades with differing degrees of substitution
• Provide taste masking